Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial
Open Access
- 17 June 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
New therapeutic strategies for patients with therapy-refractory metastatic urothelial carcinoma (mUC) are still needed. In the phase I-II ICRA trial, a multicenter, open-label, phase Ib-II clinical trial (NCT03871036), we evaluated whether paclitaxel plus tremelimumab, with or without durvalumab, could induce a tumor response in mUC following platinum chemotherapy and immune checkpoint inhibition (ICI). Patients were randomized between three arms: A (n = 20) paclitaxel plus T750mg; B (n = 12) paclitaxel plus T300mg plus D1500mg; C (n = 12) T750mg. The primary outcome, objective response rate, was met with 26% in arm A (88% CI = [14,36%]) versus 17% (88% CI = [3,42%]) in arm B and 8% (88% CI = [0.3,33%]) in arm C. Secondary outcomes included safety, duration of response and survival. Grade 3-4 treatment-related adverse events occurred in (A) 45%, (B) 75%, and (C) 25% of patients. Murine experiments showed attenuated tumor outgrowth for paclitaxel plus anti-CTLA-4 compared to monotherapy with either agent. Transcriptomic analyses showed upregulation of inflammation signatures in on-treatment tumor tissue biopsies. This study demonstrated encouraging antitumor activity in therapy-refractory mUC treated with paclitaxel plus high-dose anti-CTLA-4 and suggests immune induction may still be possible after failure to anti-PD-(L)1 therapy.Keywords
This publication has 36 references indexed in Scilit:
- ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinomaAnnals of Oncology, 2024
- CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapyImmunity, 2024
- Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeCancer, 2024
- Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicityCancer Cell, 2023
- Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT studyAnnals of Oncology, 2020
- Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder CancerEuropean Urology, 2020
- Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse Models2018
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Proper inference from Simon's two‐stage designsStatistics in Medicine, 2007
- On the estimation of the binomial probability in multistage clinical trialsStatistics in Medicine, 2004